For some patients with cancers that have been resistant to treatment, clinical trials for therapies in development are not just an interesting option – they may be their only hope. This fact motivates Ignyta to keep both patient and provider concerns top-of-mind when structuring and conducting trials. Knowing that both patients and providers are acutely concerned about the availability of trials, Ignyta is continually building an ever-growing network of study sites to bring trials closer to patients across the US and around the globe.
Accessibility is one thing; enrollment is another. The trials testing and enrollment process can be challenging for both the patient and the provider. Our exclusive Rx/Dx capability, along with in-house molecular diagnostic (Dx) testing, keeps the entire process under one roof, providing the smoothest possible enrollment process and the best communication, with the least red tape.
We believe consistent attention to both patient and provider concerns results in the best experience and the best outcomes for both.